drugset / Trial / NCT02641041

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

NCT02641041

Phase 1 Completed 24 enrolled Biogen
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The primary objective of this study is to assess the safety and tolerability of a single dose and multiple doses of BIIB033 administered to healthy adult Japanese participants. The secondary objectives of this study are to evaluate the pharmacokinetics (PK) profile of BIIB033 administered as single and multiple doses in healthy adult Japanese participants and to assess the single-dose and multiple-dose immunogenicity of BIIB033.

Timeline

Start
2016-02
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject opicinumab Protein / enzyme biologic 10 mg/kg Intravenous
Subject opicinumab Protein / enzyme biologic 30 mg/kg Intravenous
Subject opicinumab Protein / enzyme biologic 100 mg/kg Intravenous

Indications